The Zhitong Finance App learned that the biotech industry is largely driven by clinical events — the success or failure of a phase III clinical trial can not only drive large fluctuations in the stock prices of companies directly involved, but may also affect the entire category of treatment technology they represent. When a novel treatment technology passes critical clinical trials, the market's perceived risk to projects using similar methods throughout the R&D pipeline also decreases.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.